About DnaJ homolog subfamily B member 5
DnaJ homolog subfamily B member 5 (DNAJB5) is a protein
from Homo sapiens identified by UniProt accession
O75953, 348 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily B member 5 |
|---|
| UniProt accession | O75953 |
|---|
| Gene | DNAJB5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 348 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (56)
Diseases linked to this target (Open Targets).
- peripheral neuropathy · score 0.27
- Skeletal myopathy · score 0.27
- mean corpuscular hemoglobin concentration · score 0.11
- platelet count · score 0.10
- attention deficit hyperactivity disorder · score 0.09
- mean reticulocyte volume · score 0.08
- monocyte count · score 0.08
- schizophrenia 15 · score 0.07
- attention deficit-hyperactivity disorder 8 · score 0.07
- mean corpuscular volume · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75953-F1 | alphafold | PREDICTED | 80.12 | — |
Amino-acid sequence (348 residues)
MGKDYYKILG IPSGANEDEI KKAYRKMALK YHPDKNKEPN AEEKFKEIAE AYDVLSDPKK RGLYDQYGEE GLKTGGGTSG GSSGSFHYTF HGDPHATFAS FFGGSNPFDI FFASSRSTRP FSGFDPDDMD VDEDEDPFGA FGRFGFNGLS RGPRRAPEPL YPRRKVQDPP VVHELRVSLE EIYHGSTKRM KITRRRLNPD GRTVRTEDKI LHIVIKRGWK EGTKITFPKE GDATPDNIPA DIVFVLKDKP HAHFRRDGTN VLYSALISLK EALCGCTVNI PTIDGRVIPL PCNDVIKPGT VKRLRGEGLP FPKVPTQRGD LIVEFKVRFP DRLTPQTRQI LKQHLPCS
Explore DnaJ homolog subfamily B member 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets